Dynavax Technologies Corporation

Good day, ladies and gentlemen, and welcome to the Dynavox Technologies Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded. At the end of the company's prepared remarks, we will open the call for questions and provide specific participation instructions at that time. I would now like to turn the call over to Paul Cox, Vice President, Investor Relations and Corporate Communications. You may begin.

Thank you for today's call.

Joining me from Dynavax are Ryan Spencer, Chief Executive Officer, Don Cassell, Chief Commercial Officer, Rob Jansen, Chief Medical Officer, and Kelly McDonald, our Chief Financial Officer. Earlier, Dynavax released financial results for the third quarter ended September 30, 2024. Copies of the press release and a supplementary slide presentation are available on Dynavax's website. Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including but not limited to potential market sizes, market segmentation, effective marketing efforts, future market share and related growth rates, and related ACI on each. Financial guidance and trends, including revenue, profitability, cash flow, efficiency of current capitalization, timing and results of FDA submissions, clinical trial starts, and data readouts, and potential future uses of or demand for our CPG-1018 adjuvant. Adjuvants involve risks and uncertainties, and our actual results may differ materially. These risks are summarized in today's press release and detailed in the risk factor section of our SEC filings, including today's quarterly report on Form 10Q. Our forward-looking statements speak as of today, and we undertake no obligation to update such statements. And with that, I will now turn the call over to Ryan.